Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, GC AND SECRETARY | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 4,619 |
Ending reported balance
After 2026-03-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-27 · Tax withholding · Disposed 14,850 · Balance 23,287 Row 2 · 2026-03-02 · Sale · Disposed 5,777 · Balance 17,510 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-03-02 · Sale · Disposed 10,291 · Balance 7,219 F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-03-02 · Sale · Disposed 2,600 · Balance 4,619 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 3, 2026 23:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,600 | $235.26 | $611,676.00 |
DisclosureSEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,619 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 10,291 | $234.66 | $2,414,886.06 |
DisclosureSEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,219 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 5,777 | $233.51 | $1,348,987.27 |
DisclosureSEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,510 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 14,850 | $232.08 | $3,446,388.00 |
DisclosureSEC source: 0001951400-26-000006 · form4-03032026_060309.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,287 Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 7,292 | $192.86 Strike: $192.86 | $1,406,335.12 |
DisclosureSEC source: 0001951400-26-000004 · form4-02272026_050202.xml · derivative · entry 7 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,583 Underlying: Common Stock · 7,292 shares Expires 2035-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 7,775 | $175.28 Strike: $175.28 | $1,362,802.00 |
DisclosureSEC source: 0001951400-26-000004 · form4-02272026_050202.xml · derivative · entry 6 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,774 Underlying: Common Stock · 7,775 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 7,314 | $149.62 Strike: $149.62 | $1,094,320.68 |
DisclosureSEC source: 0001951400-26-000004 · form4-02272026_050202.xml · derivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,314 shares Expires 2033-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 22,381 | $230.00 | $5,147,630.00 |
DisclosureSEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,137 Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,292 | $192.86 | $1,406,335.12 |
DisclosureSEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,775 | $175.28 | $1,362,802.00 |
DisclosureSEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,314 | $149.62 | $1,094,320.68 |
DisclosureSEC source: 0001951400-26-000004 · form4-02272026_050202.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 19,500 | $0.00 Strike: $230.04 | $0.00 |
DisclosureSEC source: 0001951400-26-000002 · form4-02202026_060211.xml · derivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2036-02-17 F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,500 on February 18, 2027, 6,500 on February 18, 2028, and 6,500 on February 18, 2029. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001951400-26-000002 · form4-02202026_060211.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,137 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,628 | $0.00 | $0.00 |
DisclosureSEC source: 0001951400-26-000002 · form4-02202026_060211.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,329 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001951400-26-000002 · form4-02202026_060211.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,701 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 16,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001951400-26-000002 · form4-02202026_060211.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,909 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Disposition to issuerOption (Right to buy) · Derivative | 7,775 | $175.28 Strike: $175.28 | $1,362,802.00 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · derivative · entry 11 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,549 Underlying: Common Stock · 7,775 shares Expires 2034-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Disposition to issuerOption (Right to buy) · Derivative | 7,315 | $149.62 Strike: $149.62 | $1,094,470.30 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · derivative · entry 10 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,314 Underlying: Common Stock · 7,315 shares Expires 2033-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Disposition to issuerOption (Right to buy) · Derivative | 2,918 | $144.54 Strike: $144.54 | $421,767.72 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · derivative · entry 9 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,918 shares Expires 2032-02-16 F4 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 18,008 | $210.00 | $3,781,680.00 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 8 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,619 Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,775 | $175.28 | $1,362,802.00 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 7 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,315 | $149.62 | $1,094,470.30 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 6 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 2,918 | $144.54 | $421,767.72 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 363 | $207.19 | $75,209.97 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,619 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.12 to $207.37, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,811 | $206.62 | $1,407,288.82 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,982 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.01 to $207, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,718 | $205.38 | $558,222.84 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,793 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.99 to $205.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 7,870 | $205.02 | $1,613,507.40 |
DisclosureSEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,511 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,994 | $198.12 | $791,291.28 |
DisclosureSEC source: 0001415889-25-005291 · form4-02242025_050201.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,381 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 19, 2024. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.88 to $198.65, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 1,784 | $197.40 | $352,161.60 |
DisclosureSEC source: 0001415889-25-005291 · form4-02242025_050201.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,375 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 19, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.87 to $197.7, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 21,875 | $0.00 Strike: $192.86 | $0.00 |
DisclosureSEC source: 0001415889-25-004461 · form4-02182025_050214.xml · derivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 21,875 shares Expires 2035-02-12 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,292 on February 13, 2026, 7,292 on February 13, 2027, and 7,291 on February 13, 2028. F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,292 on February 13, 2026, 7,292 on February 13, 2027, and 7,291 on February 13, 2028. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,159 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,529 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,737 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,893 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,387 | $178.04 | $603,021.48 |
DisclosureSEC source: 0001415889-24-006162 · form4-03012024_050317.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,397 F2 · price: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 1, 2023. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.51 to $177.88, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,504 | $177.05 | $1,151,533.20 |
DisclosureSEC source: 0001415889-24-006162 · form4-03012024_050317.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,784 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.51 to $177.43, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · price: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 1, 2023. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 7,885 | $178.99 | $1,411,336.15 |
DisclosureSEC source: 0001415889-24-006162 · form4-03012024_050317.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,288 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 7,315 | $149.62 Strike: $149.62 | $1,094,470.30 |
DisclosureSEC source: 0001415889-24-005544 · form4-02272024_050202.xml · derivative · entry 7 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,629 Underlying: Common Stock · 7,315 shares Expires 2033-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 3,519 | $105.92 Strike: $105.92 | $372,732.48 |
DisclosureSEC source: 0001415889-24-005544 · form4-02272024_050202.xml · derivative · entry 6 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,519 shares Expires 2031-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 2,919 | $144.54 Strike: $144.54 | $421,912.26 |
DisclosureSEC source: 0001415889-24-005544 · form4-02272024_050202.xml · derivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,919 Underlying: Common Stock · 2,919 shares Expires 2032-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 13,753 | $177.51 | $2,441,295.03 |
DisclosureSEC source: 0001415889-24-005544 · form4-02272024_050202.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,173 F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 1, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.01 to $177.73, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,315 | $149.62 | $1,094,470.30 |
DisclosureSEC source: 0001415889-24-005544 · form4-02272024_050202.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 3,519 | $105.92 | $372,732.48 |
DisclosureSEC source: 0001415889-24-005544 · form4-02272024_050202.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 2,919 | $144.54 | $421,912.26 |
DisclosureSEC source: 0001415889-24-005544 · form4-02272024_050202.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 23,324 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004420 · form4-02202024_050232.xml · derivative · entry 5 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,324 Underlying: Common Stock · 23,324 shares Expires 2034-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,173 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,381 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,537 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 8,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004420 · form4-02202024_050232.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,399 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative return on invested capital. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 2,919 | $144.54 Strike: $144.54 | $421,912.26 |
DisclosureSEC source: 0001415889-24-002828 · form4-02062024_050202.xml · derivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,837 Underlying: Common Stock · 2,919 shares Expires 2032-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.